

Cell line name

EBiSC-NEUR1

Purpose

The purpose of this Cell Line Information Pack (CLIP) is to communicate cell line specific information to potential users of the cell line, and to confirm that a User has received it upon the purchase of an EBiSC cell line.

Information

The CLIP may provide a variety of types of information related to an individual cell line. Of particular importance are Third Party Obligations (TPOs), which are ethical or legal obligations of a Depositor related to the use of the cell line. TPOs may impose ethical or legal limitations on the ability of a User to use the cell line, or require steps to be taken before it can be used. TPOs are likely to be:

- Obligations under license to an intellectual property rights (patent) holder, or
- Restrictions on use imposed by the donor of the primary tissue from which the cell line was made.

Third Party Obligations: donor consent provisions

None.

Third Party Obligations: IP or license provisions

Related to primary material:

The following text was provided by the original provider of the primary material (Catalogue code CC-2511) from which this iPSC line was generated.

Details on the primary material can be found [here](#):

"The customer is allowed to use cells purchased from Lonza, and any cells or information derived from those original cells, for any type of research (i.e. no type of research is excluded, so genetic testing is ok). They may share the original cells and any cells or information derived from those original cells as long as whomever they share them free of cost (i.e. they may not sell the cells) and whomever they share the cells/information with is also only using them for research purposes."

Related to iPSC cells:

The following text was provided by iPS Academia: "This EBiSC product was generated under the technology disclosed in patents related to iPS cells which are owned by Kyoto University and are licensable from iPS Academia Japan., Inc. ("iPS AJ"). Commercial user (for-profit entity) acknowledges that, prior to receipt and use of this EBiSC Cell line, such commercial user needs to have an appropriate patent license from iPS AJ even for its research use. Academic user (academic or not-for-profit entity) acknowledges that such academic user does not need a patent license from iPS AJ for its research use, provided, however, that when such academic user uses this EBiSC Cell line for other than its independent research use, such academic user acknowledges that the academic user might need to obtain an appropriate patent license from iPS AJ. For inquiries to iPS AJ, please contact at license@ips-ac.co.jp."

Related to plasmids from AddGene:

Plasmids obtained from AddGene may contain technologies that are owned and/or licensed by third parties:



In case of queries, please get in touch via: Contact@EBiSC.org.

Cell line name

EBiSC-NEUR1

<https://www.addgene.org/60843/>; <https://www.addgene.org/59025/>; <https://www.addgene.org/59026/>;
<https://www.addgene.org/22077/>

Related to NGN2:

NGN2: For-profit entities using the NGN2 system to drive differentiation for commercial development e.g. compound screening needs to be aware of the patent existing and contact the patent holder, Pierre Vanderhaeghen et al (Universite Libre de Bruxelles) <https://patents.google.com/patent/WO2011091048A1/en>. The NGN2 nucleic acid sequence can, e.g. be found in the NCBI database under accession number NP_076924.1. Pursuant to the revision history, the first entry in the NCBI database was made on May 27, 2003.

Related to the Tet Technology:

The Tet Technology is controlled by TET Systems (<http://www.tetsystems.com/home/>). Details on licensing obligations and IP can be found on <http://www.tetsystems.com/home/>.

Other information

Any publications or public dissemination of results using EBiSC iPSCs should be accompanied by the following acknowledgement: "The EBiSC Bank acknowledges Bioneer A/S as the source of the human induced pluripotent cell line EBiSC-NEUR1 which was generated with support from the EBiSC2 project. The EBiSC has received support from the Innovative Medicines Initiative (IMI) Joint Undertaking (JU) under grant agreement n°115582 and from the IMI-2 JU under grant agreement No 821362, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013), European Union's Horizon 2020 research and innovation programme and EFPIA."

SIGN AND RETURN THIS DOCUMENT WITH YOUR COMPLETED ACCESS AND USE AGREEMENT

User acknowledgement

Please sign below to indicate that you have read and acknowledge the information contained in this CLIP.

Name _____ Position _____

Signature _____ Date _____

www.EBiSC.org



In case of queries, please get in touch via: Contact@EBiSC.org.